- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04612439
Accuracy of VABB Elite 10G Versus BARD 14G CNB
Accuracy of Vacuum-assisted Breast Biopsy Elite 10G Versus BARD 14G Core Needle Biopsy of Abnormal Breast Lesions.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The main purpose of the study was to analyze the difference in the accuracy of two biopsy devices in the diagnosis of breast cancer puncture. The purpose of the secondary study was to analyze the difference between the underestimation rate, false negative rate, sensitivity, and negative predictive value of the two devices, the consistency of the immunohistochemistry between the puncture pathology and surgical pathology of the two groups of patients, the number and time-consuming of the puncture acquisition specimens, and the two biopsies Differences in the incidence of complications (safety).
If the biopsy device is a vacuum-assisted Elite 10G needle, insert the needle groove into the mass and rotate to cut the biopsy tissue one circle; If the biopsy device is a BARD 14G hollow core needle, insert the needle to the edge of the mass and pull the trigger in different directions to eject the needle to retrieve the material.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Shanghai, China
- Fudan University Shanghai Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Over 18 years old (including 18 years old)
- Ultrasound examination indicates the presence of space-occupying lesions in the breast. The size, location, and BI-RADS classification are not limited.
- Agree to undergo surgery after puncture
- Ability and willingness to sign informed consent
Exclusion Criteria:
- A biopsy has been performed in the external hospital
- Contraindications for puncture or surgery such as severe coagulation dysfunction
- Refuse breast surgery
- Axillary lymph node puncture
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: VABB Elite 10G
Vacuum-assisted Elite 10G
|
If the biopsy device is a vacuum-assisted Elite 10G needle, insert the needle groove into the mass and rotate to cut the biopsy tissue one circle
|
Active Comparator: BARD 14G CNB
BARD 14G Core needle
|
If the biopsy device is a BARD 14G hollow core needle, insert the needle to the edge of the mass and pull the trigger in different directions to eject the needle to retrieve the material
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Accuracy
Time Frame: 3 months
|
The accuracy of the puncture pathology was defined as the proportion of patients in the study population who were consistent with the qualitative diagnosis of the puncture pathology and surgical pathology.When the pathological diagnosis of puncture is "carcinoma in situ of the catheter", if the pathological diagnosis of the catheter is "carcinoma in situ of the catheter with microinfiltration", the puncture is considered accurate;If the surgical pathology confirms "invasive cancer (infiltrating lesion >1mm)", the pathology of the puncture is considered inaccurate (ie, underestimated)
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Concordance of immunohistochemical marker status
Time Frame: 3 months
|
ER,PR, HER2and Ki67from tissues obtained by percutaneous biopsy and follow on surgical procedure.
|
3 months
|
Sensitivity
Time Frame: 3 months
|
The proportion of patients with abreast cancer diagnosis by percutaneous biopsy among all patients receiving an invasive breast cancer diagnosis by either percutaneous biopsy or by follow on surgical procedure.
|
3 months
|
Negative Prediction Value
Time Frame: 3 months
|
The proportion of patients whose diagnosis from percutaneous biopsy is benign, among all patients with a benign diagnosis by follow on surgical procedure, ORthe proportion of patients whose diagnosis from percutaneous biopsy is benign, among all patients whose malignant lesions were not diagnosed within less than 1 year of follow-up after initial percutaneous biopsy.
|
3 months
|
Underestimation Rate
Time Frame: 3 months
|
The rate at which the surgical procedure following a percutaneous biopsy upgrades or upstages the severity of histopathologic diagnosis.
For example, a) if percutaneous biopsy indicated benign lesions, and the subsequent surgical procedureidentifiedprecancerous lesions (e.g., ADH) or malignant lesions (DCIS or invasive adenocarcinoma); or b) if percutaneous biopsy indicated precancerous lesions, and follow up surgical procedureidentified malignant lesions(DCIS or invasive adenocarcinoma); or 3) if percutaneous biopsyindicated carcinoma in situ,and follow up surgical procedure identified infiltrating carcinoma (except microinvasive foci <1mm) identified by follow onsurgical procedure.
|
3 months
|
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Time Frame: 7 days
|
Rate of immediate bleeding on the day of puncture (bleeding requiring a compression bandage); rate of bleeding that cannot be stopped by a compression bandage within 48 hours after procedure; rate of hematoma on the second day after puncture; rate of skin ecchymosis and puncture point infection (local redness, swelling, heat and pain).
|
7 days
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Junjie Li, MD, Fudan University
- Principal Investigator: Ying Zhang, MD, Fudan University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 2008222-12
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
Clinical Trials on VABB Elite 10G
-
ResMedCompletedObstructive Sleep ApneaUnited States
-
Vivasure Medical LimitedNot yet recruitingLarge Hole Percutaneous Venous Closure
-
Goldman, Butterwick, Fitzpatrick and GroffRecruitingImproved Appearance of the Banana Roll RegionUnited States
-
AllerganCompletedNon-invasive Fat ReductionUnited States, France, Singapore, Sweden, Germany
-
University of Alabama at BirminghamCompletedExogenous KetosisUnited States
-
Vivasure Medical LimitedNot yet recruitingLarge Hole Percutaneous Arterial Closure
-
Prim. Prof. Dr. Oliver Findl, MBAUnknown
-
Centre hospitalier de l'Université de Montréal...University of British Columbia; Western University, Canada; University of Saskatchewan and other collaboratorsNot yet recruiting
-
Wake Forest University Health SciencesNovadaq Technologies ULC, now a part of StrykerCompletedVentral HerniaUnited States